Defender Capital, a shareholder of STAAR Surgical Co., opposes the proposed acquisition by Alcon Inc., stating that the $28 per share offer significantly undervalues the company. STAAR’s Board had previously rejected a $58 per share offer from Alcon. Defender Capital is disappointed in the Board’s decision, citing positive projections and an optimistic outlook from STAAR’s management. The views expressed in the statement are those of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more at Nasdaq: Defender Capital Opposes STAAR Surgical’s Proposed Acquisition By Alcon